Definition

A preparation of allogeneic, off-the-shelf (OTS), universal, gene-edited T lymphocytes expressing a fourth-generation chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD7 CAR T cells 4SCAR7U specifically target and kill CD7-expressing tumor cells. CD7 is a transmembrane glycoprotein expressed by T cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.